Market Scenario
As per the data experts at Market Research Future (MRFR), the chronic lymphocytic leukemia treatment market was worth USD 7.9 Billion in 2017. Additionally, the market is expected to expand at a growth rate of 19% over the forecast period (2018-2023).
Market Drivers and Key Challenges
Chronic lymphocytic leukemia is considered to be one of the most common types of leukemia in adults. This type of cancer involves the development of lymphocytes, which are white blood cells, within the bone marrow. The lymphocytic leukemia cells are generally present in the lymph nodes along with various other tissues. There are two primary types of chronic lymphocytic leukemia, wherein one grows slowly, and the other is considered fatal. In general, one does not experience any symptoms due to chronic lymphocytic leukemia for a long period. However, the symptoms usually noted include fatigue, easy bruising, and swollen lymph nodes.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6900
Generally, the most popular form of treatment for CLL is chemotherapy, whereas stem-cell transplant is for rare cases. An article published by Apollo Hospitals states that in India, roughly one million cases of chronic lymphocytic leukemia are diagnosed annually. As per the cancer statistics, 1 in every 155 men and 1 in every 260 women get affected with CLL in their lifetime, in the United Kingdom (U.K). The boost in cancer cases around the world, innovations in drug therapy, quick regulatory approval processes, and vigorous pipeline of drugs for chronic lymphocytic leukemia treatment are additional factors substantiating the growth of the chronic lymphocytic leukemia market.
Having said that, the stunted level of awareness with regard to symptoms is expected to retard the market growth in the forthcoming years. However, growing research & development activities coupled with continuous technological developments in the field is presumed to augment the market growth to a large extent.
Market Segmentation
The global chronic lymphocytic leukemia treatment market has been segmented on the basis of type, treatment, and end user.
The market, in terms of the type, has been considered for indolent CLL and aggressive CLL.
The market, treatment-wise, can be broken down into chemotherapy, targeted drug therapy, immunotherapy, and bone marrow transplant.
The end users in the global market are hospitals & clinics, diagnostic laboratories, research institutes, and others.
Prominent Players
The prominent vendors within the worldwide chronic lymphocytic leukemia treatment market include Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Genmab A/S, TG Therapeutics, Inc., Ziopharm Oncology, F. Hoffmann-La Roche Ltd, AbbVie Inc., Genentech, Inc., Gilead, Genzyme Corporation, ONO PHARMACEUTICAL CO., LTD., GlaxoSmithKline plc, CELGENE CORPORATION, Inc., Johnson & Johnson Services, Inc., and others.
Browse Full Report Details @ https://www.marketresearchfuture.com/reports/chronic-lymphocytic-leukemia-treatment-market-6900
No comments:
Post a Comment